National Institutes of Health
In addition to several undisclosed collaborations with leading pharmaceutical companies, BlueWillow has a strategic relationship with NIH supporting the development of certain key intranasal vaccines:
BlueWillow has an ongoing $10 million contract with the National Institute of Allergy and Infectious Diseases (NIAID), a division of the NIH, to develop its intranasal platform for use with pandemic influenza vaccines. The company also has a partnership with Public Health England (PHE) to develop an intranasal anthrax vaccine through Phase 1 under a $24 million contract award from NIAID.
BlueWillow’s intranasal vaccine programs for HSV-2 and chlamydia are currently supported by recent NIH SBIR grants. The company also has an active agreement with the Division of Microbiology and Infectious Diseases (DMID), a division of NIAID. Under the agreement, DMID has agreed to fund certain studies in support of developing intranasal vaccines for RSV, HSV-2 and pertussis. In addition, BlueWillow has an ongoing collaboration with Washington University in St. Louis for the development of an intranasal vaccine for TB, with support from NIH.